drugset / Trial / NCT00934479
Intestinal Microecology in Chronic Constipation
Phase 1
Completed
21 enrolled
Mayo Clinic
Arizona State University · collabTakeda Pharmaceuticals North America, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to determine whether the bacteria normally present in the bowels are different in people with constipation and to see what effect the treatment with the Food and Drug Administration (FDA) - approved drug, lubiprostone, has on these bacteria.
Timeline
- Start
- 2010-04
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lubiprostone | Small molecule | 8 ug | Oral |
| Subject | Lubiprostone | Small molecule | 24 ug | Oral |